Cancer-Associated Thrombosis in Patients Treated with Immune Checkpoint Inhibitors
International Journal of Molecular Sciences · 15.02.2026 · 27 (4) · 1874
DOI: 10.3390/ijms27041874 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.02.2026. Verfasst von Alice Ilari und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Unit, IRCCS Fondazione San Gerardo dei Tintori, 20900 Monza, Italy. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Thrombosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The incidence of cancer-associated thrombosis has increased in recent years. While the association between venous thromboembolism (VTE) and chemotherapy is well established, there is no clear link between immune checkpoint inhibitors (ICIs) and VTE risk. Many risk assessment models (RAMs) have been developed to identify high-risk patients who need prophylaxis. However, these models are validated in patients undergoing chemotherapy, while they are scarce in those receiving immunotherapy. Moreover, the mechanisms linking ICIs to thrombosis are still a matter of debate. They include the upregulation of pro-inflammatory intracellular pathways, the release of cytokines, the activation of innate immune cells, the release of tissue factors and platelet activation, and the increase in adhesion molecules, thus resulting in the recruitment of agents involved in coagulation. Promising biomarkers are emerging to identify patients undergoing ICIs who are at high risk of developing VTE and need prophylaxis. In this review we investigate the possible causation between cancer-associated thrombosis (CAT) and immunotherapy and the underlying pathophysiological mechanisms. Thus, we suggest the most appropriate therapeutic approaches based on currently available data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Unit, IRCCS Fondazione San Gerardo dei Tintori, 20900 Monza, Italy.
- Department of Clinical Medicine, University of Milano-Bicocca, 20900 Monza, Italy.
- Internal, Vascular and Emergency Medicine-Stroke Unit, Department of Medicine and Surgery, University of Perugia, 06123 Perugia, Italy.
- Medicine and Surgery Department, University of Brescia, 25121 Brescia, Italy.
ORCID-Profile: Luca Sala, Diego Luigi Cortinovis, Stefania Canova
Zitieren
APA
Ilari, A., Abbate, M. I., Verso, M., Graziani, M., Cafaro, P., Sala, L., Colonese, F., Cortinovis, D. L., & Canova, S. (2026). Cancer-Associated Thrombosis in Patients Treated with Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 27(4), 1874. https://doi.org/10.3390/ijms27041874
Vancouver
Ilari A, Abbate MI, Verso M, Graziani M, Cafaro P, Sala L, et al. Cancer-Associated Thrombosis in Patients Treated with Immune Checkpoint Inhibitors. International Journal of Molecular Sciences. 2026;27(4):1874. doi:10.3390/ijms27041874
BibTeX
@article{Ilari2026,
author = {Ilari, Alice and Abbate, Maria Ida and Verso, Melina and Graziani, Mara and Cafaro, Pietro and Sala, Luca and Colonese, Francesca and Cortinovis, Diego Luigi and Canova, Stefania},
title = {Cancer-Associated Thrombosis in Patients Treated with Immune Checkpoint Inhibitors},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {4},
pages = {1874},
doi = {10.3390/ijms27041874}
}
EUVIMED